Background/Aims: This prospective study was conducted to investigate the feasibility of an early discontinuation of thyroid hormone treatment in very-low-birth-weight (VLBW) infants with congenital hypothyroidism (CH). Methods: We enrolled VLBW infants between January 2011 and December 2012. The infants were divided into the hypothyroid and normal thyroid function groups according to the results of a thyroid function test. We performed an early off-therapy trial at 24 months of age. Results: Of the 182 VLBW infants enrolled, 15 were lost to follow-up and 167 were finally enrolled. In total, 24 infants (14.4%) were assigned to the hypothyroid function group and were treated with thyroid hormone. Younger gestational age and a lower birth weight were associated with hypothyroid function. In the hypothyroid function group, hypothyroidism (HT) and hyperthyrotropinemia (HTT) were observed in 13 and 11 infants, respectively. There were no differences in the clinical characteristics between the HT and HTT groups. Overall, 24 infants discontinued thyroxine medication at 24 months of age after normal results had been confirmed by radiologic work-ups, including thyroid ultrasonography and technetium-99m scans. All infants were successfully weaned off thyroxine and maintained euthyroid function. Conclusion: Early discontinuation of thyroid hormone replacement therapy is possible in the majority of VLBW infants with CH.

Keywords:
Congenital hypothyroidism, Hyperthyrotropinemia, Very-low-birth-weight infants
1.
Grosse SD, Van Vliet G: Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level? Arch Dis Child 2011;96:374-379.
2.
Fisher DA: Disorders of the Thyroid in the Newborn and Infant. Clinical Pediatric and Adolescent Endocrinology. Philadelphia, Saunders, 2002, p 164.
3.
Kemper AR, Ouyang L, Grosse SD: Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. BMC Pediatr 2010;15:9.
4.
Deladoey J, Ruel J, Giguere Y, Van Vliet G: Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Quebec. J Clin Endocrinol Metab 2011;96:2422-2429.
5.
Albert BB, Cutfield WS, Webster D, Carll J, Derraik JG, Jefferies C, Gunn AJ, Hofman PL: Etiology of increasing incidence of congenital hypothyroidism in New Zealand from 1993-2010. J Clin Endocrinol Metab 2012;97:3155-3160.
6.
Parks JS, Lin M, Grosse SD, Hinton CF, Drummond-Borg M, Borgfeld L, Sullivan KM: The impact of transient hypothyroidism on the increasing rate of congenital hypothyroidism in the United States. Pediatrics 2010;125(suppl 2):S54-S63.
7.
Chung HR, Shin CH, Yang SW, Choi CW, Kim BI, et al: High incidence of thyroid dysfunction in preterm infants. Neonatal Med 2009;24:627-631.
8.
Radetti G, Fanolla A, Pappalardo L, Gottardi E: Prematurity may be a risk factor for thyroid dysfunction in childhood. J Clin Endocrinol Metab 2007;92:155-159.
9.
Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundarajan S, Varma SK: Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006;117:2290-2303.
10.
Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G; ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE; Congenital Hypothyroidism Consensus Conference Group: European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr 2014;81:80-103.
11.
Cho MS, Cho GS, Park SH, Jung MH, Suh BK, Koh DG: Earlier re-evaluation may be possible in pediatric patients with eutopic congenital hypothyroidism requiring lower L-thyroxine doses. Ann Pediatr Endocrinol Metab 2014;19:141-145.
12.
Lim G, Lee YK, Han HS: Early discontinuation of thyroxine therapy is possible in most very low-birthweight infants with hypothyroidism detected by screening. Acta Pediatr 2014;103:123-129.
13.
Sperling MA: Pediatric Endocrinology, ed 3. Philadelphia. Saunders, 2008, p 216.
14.
Hern S, Heuer H: Thyroid hormone action during brain development: more questions than answers. Mol Cell Endocrinol 2010;315:19-26.
15.
Gruters A, Jenner A, Krude H: Long-term consequences of congenital hypothyroidism in the era of screening programs. Best Pract Res Clin Endocr Metab 2002;16:369-382.
16.
Fisher DA, Dussault JH, Foley TP Jr, Klein AH, LaFranchi S, Larsen PR, Mitchell ML, Murphey WH, Walfish PG: Screening for congenital hypothyroidism: results of screening one million North American infants. J Pediatr 1979;94:700-705.
17.
Mitchell ML, Hsu HW, Sahai I; Massachusetts Pediatric Endocrine Work Group: The increased incidence of congenital hypothyroidism: fact or fancy? Clin Endorinol (Oxf) 2011;75:806-810.
18.
Mengreli C, Kanaka-Gantenbein C, Girginoudis P, et al: Screening for congenital hypothyroidism: the significance of threshold limit in false-negative results. J Clin Endocrinol Metab 2010;95:4283-4290.
19.
Olivieri A, Fazzini C, Medda E; Italian Study Group for Congenital Hypothyroidism: Multiple factors influencing the incidence of congenital hypothyroidism detected by neonatal screening. Horm Res Pediatr 2015;83:86-93.
20.
Kruinczuk JJ, Bower C, Lewis B, Byrne G: Congenital hypothyroidism in Western Australia 1981-1998. J Paediatr Child Health 2002;38:187-191.
21.
Corbetta C, Weber G, Cortinovis F, Calebrio D, Passoni A, Vigone MC, Beck-Peccoz P, Chiumello G, Persani L: A 7-year experience with low blood TSH cutoff levels for neonatal screening reveals an unsuspected frequency of congenital hypothyroidism (CH). Clin Endocrinol (Oxf) 2009;71:739-745.
22.
Ford G, LaFranchi SH: Screening for congenital hypothyroidism: a worldwide view of strategies. Best Pract Res Clin Endocrinol Metab 2014;28:175-187.
23.
Woo HC, Lizarda A, Tucker R, Mitchell ML, Vohr B, Oh W, Phomphutkul C: Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes. J Pediatr 2011;158:538-542.
24.
Fisher DA: Thyroid system immaturies in very low birth weight premature infants. Semin Perinatol 2008;32:387-397.
25.
Glombek SG: Nonthyroidal illness syndrome and euthyroid sick syndrome in intensive care patients. Semin Perinatol 2008;32:413-418.
26.
Larson C, Hermos R, Delaney A, Daley D, Mitchell M: Risk factors associated with delayed thyrotropin elevations in congenital hypothyroidism. J Pediatr 2003;143:587-591.
27.
Vermiglio F, Lo Presti VP, Scaffidi Argentina G, Finocchiaro MD, Gullo D, Squartrito S, Trimarchi F: Maternal hypothyroxinaemia during the first half of gestation in an iodine deficient area with endemic cretinism and related disorders. J Clin Endocrinol 1995;42:409-415.
28.
Schoen EJ, Clapp W, To TT, Fireman BH: The key role of newborn thyroid scintigraphy with isotopic iodide (123I) in defining and managing congenital hypothyroidism. Pediatrics 2004;114:683-688.
29.
Tamam M, Adalet I, Bakir B, Türkmen C, Darendeliler F, Baş F, Sanli Y, Kuyumcu S: Diagnostic spectrum of congenital hypothyroidism in Turkish children. Pediatr Int 2009;51:464-468.
30.
Mandel SJ, Hermos RJ, Larson CA, Prigozhin AB, Rojas DA, Mitchell ML: Atypical hypothyroidism and very low birth weight infant. Thyroid 2000;10:693-695.
31.
Korzeniewski SJ, Grigorescu V, Young WI: Congenital hypothyroid screening among low birth weight infants, Michigan, 2005-2007. Maternal and Child Health Epidemiology Conference, 2008, Atlanta.
32.
DeGroot LJ: ‘Non-thyroidal illness syndrome' is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge. J Endocrinol Invest 2003;26:1163-1170.
33.
Filippi L, Pezzati M, Cecchi A, Poggi C: Dopamine infusion: a possible cause of undiagnosed congenital hypothyroidism in preterm infants. Pediatr Crit Care Med 2006;7:249-251.
34.
Williams FL, Ogston SA, van Toor H, Visser TJ, Hume R: Serum thyroid hormones in preterm infants: associations with postnatal illnesses and drug usage. J Clin Endocrinol Metab 2005;90:5954-5963.
35.
Ares S, Escobar-Morreale HF, Quero J, Duran S, Presas MJ, et al: Neonatal hypothyroxinemia: effects of iodine intake and premature birth. J Clin Endocrinol Metab 1997;82:1704-1712.
36.
Ibrahim M, de Escobar GM, Visser TJ, Duran S, van Toor H, et al: Iodine deficiency associated with parenteral nutrition in extreme preterm infants. Arch Dis Child Fetal Neonatal Ed 2003;88:56-57.
37.
Vigone MC, Caiulo S, Di Frenna M, Ghirardello S, Corbetta C, Mosca F, Weber G: Evolution of thyroid function in preterm infants detected by screening for congenital hypohtyrodism. J Pediatr 2014;164:1296-1302.
38.
Wang X, Jiang L, Wu L: Effects of aminophylline on the secretion of thyroid hormones and the changes of heart rate and rhythm. J Biochem Eng 2001;81:567-568.
39.
Chung ML, Yoo HW, Kim KS, Lee BS, Pi SY, Lim G, Kim EA: Thyroid dysfunctions of prematurity and their impacts on neurodevelopmental outcome. J Pediatr Endocrinol Metab 2013;26:449-455.
40.
Korzeniewski SJ, Grigorescu V, Kleyn M, Young WI, Birbeck G, Todem D, Romero R, Paneth N: Transient hypothyroidism at 3- year follow-up among cases of congenital hypothyroidism detected by newborn screening. J Pediatr 2013;162:177-182.
41.
Hinton CF, Harris KB, Borgfeld L, Drummond-Borg M, Eaton R, Lorey F, Therrell BL, Wallace J, Pass KA: Trends in incidence rates of congenital hypothyroidism related to select demographic factors: data from the United States, California, Massachusetts, New Texas. Pediatrics 2010;125:S37-S47.
42.
Rabbiosi S, Vigone MC, Cortinovis F, Zamproni I, Fugazzola L, Persani L, Corbetta C, Chiumello G, Weber G: Congenital hypothyroidism with eutopic thyroid gland: analysis of clinical and biochemical features at diagnosis and after re-evaluation. J Clin Endocrinol Metab 2013;98:1395-1402.
43.
Bhavani N: Transient congenital hypothyroidism. Indian J Endorinol Metab 2011;15:117-120.
44.
Bongers-Schokking JJ, Resing WC, de Rijke YB, de Ridder MA, de Muinck Keizer-Schrama SM: Cognitive development in congenital hypothyroidism: is overtreatment a greater threat than undertreatment? J Clin Endocrinol Metab 2013;98:4499-4506.
45.
Jones JH, Gellén B, Paterson WF, Beaton S, Donaldson MD: Effect of high versus low initial doses of L-thyroxine for congenital hypothyroidism on thyroid function and somatic growth. Arch Dis Child 2008;93:940-944.
46.
Gaudino R, Garel C, Czernichow P, Léger J: Proportion of various types of thyroid disorders among newborns with congenital hypothyroidism and normally located gland: a regional cohort study. Clin Endocrinol 2005;62:444-448.
47.
Hong SY, Chung HR, Lee SY, Shin CH, Yang SW: Factors distinguishing between transient and permanent hypothyroidism in patients diagnosed as congenital hypothyroidism by newborn screening. J Korean Soc Pediatr Endocrinol 2005;10:154-160.
48.
Lim HK, Kim KH, Kim SH, No HY, Kim CJ, Woo YJ, Hwang TJ: Predictors of transient hypothyroidism in neonatal screening test. J Korean Soc Pediatr Endorinol 2006;11:50-56.
49.
Unüvar T, Demir K, Abacı A, Büyükgebiz A, Böber E: The role of initial clinical and laboratory findings in infants with hyperthyrotropinemia to predict transient or permanent hypothyroidism. J Clin Res Pediatr Endocrinol 2013;10:170-173.
50.
Graber E, Regelmann MO, Annunziato R, Machac J, Rapaport R: The role of 123I imaging in the evaluation of infants with mild congenital hypothyroidism. Horm Res Paediatr 2015;83:94-101.
51.
Zung A, Tenenbaum-Rakover Y, Barkan S, Hanukoglu A, Hershkovitz E, Pinhas-Hamiel O, Bistritzer T, Zadik Z: Neonatal hyperthyrotropinemia: population characteristics, diagnosis, management and outcome after cessation of therapy. Clin Endocrinol (Oxf) 2010;72:264-271.
52.
Skordis N, Toumba M, Savva SC, Erakleous E, Topouzi M, Vogazianos M, Argyriou A: High prevalence of congenital hypothyroidism in the Greek Cypriot population: results of the neonatal screening program 1990-2000. J Pediatr Endocrinol Metab 2005;18:453-461.
53.
Ghasemi M, Hashemipour M, Hovsepian S, Heiydari K, Sajadi A, Hadian R, et al: Prevalence of transient congenital hypothyroidism in central part of Iran. J Res Med Sci 2013;18:699-703.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.